Nat. Biotechnol. 28, 881–882 (2010); published online 9 September 2010; corrected after print 22 September 2010
In the version of this article initially published, it was reported that GlaxoSmithKline's (GSK's) EpiNova was one of several “biotech-like ideas” that “have been known to fizzle in pharma hands”; in fact, EpiNova has not “fizzled” but is in its second year of operation as a discovery performance unit of GSK focusing on epigenetic approaches to autoimmune disease. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0910-881
Rights and permissions
About this article
Cite this article
Shaffer, C. Erratum: Pfizer explores rare disease path. Nat Biotechnol 28, 1129 (2010). https://doi.org/10.1038/nbt1010-1129a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1010-1129a
